LAURA BIANEZ: Open Payments
NPI 1568489482 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,647 in 252 payments from 50 companies in 2025. Trend: 2023 $6,062 · 2024 $6,526 · 2025 $7,647
Food & beverage: $6,169Long term medical supply or device loan: $1,097Education: $400
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 26 | $1,410 |
| Janssen Biotech, Inc. | 22 | $877 |
| Daiichi Sankyo Inc. | 28 | $522 |
| AstraZeneca Pharmaceuticals LP | 14 | $415 |
| Incyte Corporation | 13 | $337 |
| GENZYME CORPORATION | 9 | $266 |
| GlaxoSmithKline, LLC. | 7 | $255 |
| PFIZER INC. | 10 | $248 |
| Astellas Pharma US Inc | 5 | $204 |
| ABBVIE INC. | 7 | $169 |
Products named: KISQALI, RYBREVANT, Enhertu, JEMPERLI, KEYTRUDA, Trodelvy, TECVAYLI, JAKAFI.
Industry payments across TX — which companies pay providers there.
